<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01702610</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-08-013</org_study_id>
    <secondary_id>MGRT01:TMZ/GBM</secondary_id>
    <nct_id>NCT01702610</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with GBM, who were deemed ineligible for any active protocols at our centre,&#xD;
      received accelerated hypofractionation EBRT if 60Gy/20Fx using an IMRT technique with&#xD;
      conventional dose of concomitant and adjuvant TMX as per the STUPP's TMZ schedule. Thirty&#xD;
      five patients, 15 females and 20 males with a median age of 63 (range 31-78) were treated&#xD;
      with a median KPS of 90 (range 50-100). Four patients had multicentric disease at&#xD;
      presentation. Eight patients had biopsy only while the rest had a near total resection (n=14)&#xD;
      and partial resection (n=13) with a median follow-up of 12.1 months, the median survival was&#xD;
      14.4 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this proposal, the total cumulative dose of TMZ is unchanged as compared to the doses used&#xD;
      in the Stupp protocol. In this proposal, the dose of TMZ is the same, with the sole&#xD;
      difference that TMZ will be given in a neo-adjuvant setting for two weeks and then continued&#xD;
      at the same dose concurrently with the accelerated hypofractionated EBRT delivering 60Gy in 4&#xD;
      weeks. The adjuvant component of TMZ remains unchanged from current standard practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients completing the study treatment</measure>
    <time_frame>At one year</time_frame>
    <description>To determine overall survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess toxicity of the regimen</measure>
    <time_frame>At one year</time_frame>
    <description>Toxicity will be assessed and graded according to CTCAE-V3</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Glioblastoma Mutliforme</condition>
  <arm_group>
    <arm_group_label>Temozolomide, Accelerated Hypofractionated RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT Technique</intervention_name>
    <arm_group_label>Temozolomide, Accelerated Hypofractionated RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT and accelerated hypofractionation technique</intervention_name>
    <description>Intervention is the technique and accelerated fractionation used to treat GBM</description>
    <arm_group_label>Temozolomide, Accelerated Hypofractionated RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neo-adjuvant TMZ followed by accelerated hypofractionated EBRT</intervention_name>
    <description>Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component</description>
    <arm_group_label>Temozolomide, Accelerated Hypofractionated RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide and Accelerated Hypofractionation RT</intervention_name>
    <arm_group_label>Temozolomide, Accelerated Hypofractionated RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years or older&#xD;
&#xD;
          -  Histological confirmation of supratentorial GBM&#xD;
&#xD;
          -  KPS &gt; 60&#xD;
&#xD;
          -  Neurological function 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow as defined below:&#xD;
&#xD;
          -  absolute neutrophil count (ANC) &gt; 1500 cells/mm3&#xD;
&#xD;
          -  platelets &gt; 100,000 cells/mm3&#xD;
&#xD;
          -  hemoglobin &gt; 10g/dl&#xD;
&#xD;
          -  Adequate renal function as defined below:&#xD;
&#xD;
          -  BUN &lt; 25mg/dl within 14 days prior to study registration&#xD;
&#xD;
          -  creatinine of 63 to 103 umol/L within 14 days prior to study registration&#xD;
&#xD;
          -  Adequate hepatic function as defined below:&#xD;
&#xD;
          -  Bilirubin of 3 to 21 umol/L within 14 days prior to study registration&#xD;
&#xD;
          -  ALT &amp; AST &lt; 3xnormal range within 14 days prior to study registration&#xD;
&#xD;
          -  Neoadjuvant TMZ to start within 3 weeks of surgery/biopsy if no resection was deemed&#xD;
             feasible&#xD;
&#xD;
          -  A diagnostic contrast-enhanced MRI or CT scan of the brain must be performed&#xD;
             preoperatively and postoperatively.&#xD;
&#xD;
          -  History, physical and neurological examination within 14 days prior to study&#xD;
             registration.&#xD;
&#xD;
          -  For females of child-bearing potential, negative pregnancy test within 72 hours prior&#xD;
             to starting TMZ.&#xD;
&#xD;
          -  Able to sign an informed study-specific consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Margin of contrast-enhanced residual mass closer than 15mm from the optic chiasm or&#xD;
             optic nerves.&#xD;
&#xD;
          -  Prior invasive malignancy, unless disease-free for &gt;3years&#xD;
&#xD;
          -  Recurrent or multifocal GBM&#xD;
&#xD;
          -  Severe co-morbidities such as&#xD;
&#xD;
          -  unstable angina&#xD;
&#xD;
          -  transmural myocardial infarction within 6 months&#xD;
&#xD;
          -  COPD at the time of registration&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Bacterial or fungal infection requiring IV antibiotics at the time of registration&#xD;
&#xD;
          -  Acquired Immune Deficiency Syndrome (AIDS)&#xD;
&#xD;
          -  Major medical illnesses or psychiatric impairments&#xD;
&#xD;
          -  Pregnant women or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2012</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>George Shenouda</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

